Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06041789

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism factors including bone mineral density, bone turnover markers, and bone quality.

Participants in this study will have a bone density test and have blood samples collected at the baseline study visit. Participants will then be randomly assigned to donepezil or matching memantine to be taken daily by mouth for 12 months. Blood samples will be collected at 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will also complete questionnaires at each study visit.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Duke Memory Disorders Clinic

Durham, North Carolina, 27705, United States

Location status: Recruiting

Location contact

Connie Thacker

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of cognitive impairment, including clinical assessment, radiographic or laboratory biomarker assessment
  • Willing to initiate treatment for cognitive impairment
  • A) For females: either age > 55 years, or Age < 55 years and at least 12 months since last menstrual period B) For males, age > 50 years
  • Geriatric Depression Scale score < 6
  • English-speaking

Exclusion criteria

  • Currently on acetylcholinesterase inhibitor or memantine
  • History of bradycardia, heart block, long QT, unexplained syncope, or other contraindication for donepezil; subject with ECG showing HR < 50, PR interval > 200 ms, QTc > 440 ms in men or > 460 ms in women, or evidence of atrioventricular block
  • Currently on osteoporosis medication (e.g., bisphosphonate, SERM, denosumab, teriparatide, abaloparatide, romozosumab, calcitonin)
  • Use of bisphosphonate within last 5 years
  • Use within last 6 months of estrogens or testosterone, androgen deprivation therapy or aromatase inhibitors, antiepileptic, heparin therapy, thiazolidinediones
  • History of disorders associated with secondary osteoporosis: collagen vascular diseases, malabsorption, inflammatory bowel disease, severe liver disease/cirrhosis, hyperthyroidism (endogenous or exogenous)
  • History of fracture of the humerus, wrist, or vertebra due to fall from standing height or less
  • History of hip fracture, hip replacement, or non-ambulatory
  • Long-term use (>6 months) of corticosteroids
  • History of Parkinson's, HIV, Huntington's disease
  • History of solid organ transplantation
  • History of bariatric surgery or intending to lose weight by bariatric surgery or weight loss medication (e.g. GLP-1 agonist) in the next 12-months
  • Severe kidney impairment (eGFR < 30 ml/min),
  • Active malignancy currently undergoing chemotherapeutic, surgical, or radiation therapy, except non-melanomatous skin cancer
  • 1-year mortality > 25%, measured by ePrognosis calculator
  • Planning to move out of the area in the next 12-months
  • Planning surgery in the next 12-months

Treatment and study plan

Donepezil

Drug

10 mg tablet

Memantine

Drug

10 mg tablet

Primary outcomes

  1. Change in bone mineral density, as measured by dual x-ray absorptiometry (DXA)

    Time frame: baseline, 12 months

Secondary outcomes

  1. Change in bone resorption marker C-terminal telopeptide (CTX)

    Time frame: baseline, 6 months, 12 months

    measured using commercially available ELISA test on serum

  2. Change in bone formation marker amino-terminal propeptide of type I procollagen (P1NP)

    Time frame: baseline, 6 months, 12 months

    measured using commercially available ELISA test on serum

  3. Change in Trabecular Bone score

    Time frame: baseline, 12 months

    measure of bone quality, using DXA spine images

Study contacts

Contact information is provided by the study sponsor or research team.

Susanne Danus

CONTACT

[email protected]

(919) 681-9807

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 18, 2023
Registry last updated
Sep 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.